Drug intelligence / Profile preview

FX-111

Development stage: Phase 1
Lead developer: Flare Therapeutics
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

FX-111 is a novel, highly differentiated, potent, and selective degrader of the transcriptionally active androgen receptor (ARON). It is being developed by Flare Therapeutics for the treatment of metastatic castration-resistant prostate cancer (mCRPC). FX-111 aims to overcome key vulnerabilities of conventional therapies targeting AR by focusing on the active and hormone-bound form of the androgen receptor[1].

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on FX-111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FX-111.

Explore the full profile